PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34359966-8	2021	Reproducible IL-4-dependent expansion and enrichment of CAR-engineered T-cells under GMP was achieved, both from patients and healthy donors.	guanosine 5'-monophosphorothioate	85-88	nuclear receptor subfamily 1 group I member 3	Homo sapiens	56-59	
35401506-0	2022	GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.	guanosine 5'-monophosphorothioate	0-3	nuclear receptor subfamily 1 group I member 3	Homo sapiens	39-42	
35401506-3	2022	Based on our previous development and validation of automated and closed processing for GMP-compliant manufacturing of CAR T cells, we here present the proof of feasibility for translation of this method to TRUCKs.	guanosine 5'-monophosphorothioate	88-91	nuclear receptor subfamily 1 group I member 3	Homo sapiens	119-122	
31426437-0	2019	Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.	guanosine 5'-monophosphorothioate	136-139	nuclear receptor subfamily 1 group I member 3	Homo sapiens	29-32	
31426437-0	2019	Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.	guanosine 5'-monophosphorothioate	136-139	nuclear receptor subfamily 1 group I member 3	Homo sapiens	121-124	
31426437-3	2019	Here we present the clinical-scale production of CAR-T cells for the treatment of melanoma under full GMP compliance.	guanosine 5'-monophosphorothioate	102-105	nuclear receptor subfamily 1 group I member 3	Homo sapiens	49-52